Form 4: Tenaya Therapeutics Director and 10% Owner Granted Significant Stock Options

David V. Goeddel, a Director and 10% Owner of Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444, vesting over the next year.

Summary

• David V. Goeddel, a Director and 10% Owner of Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options.
• The options have an exercise price of $0.4444 per share.
• The grant date for these options was May 29, 2025.
• The options are set to vest in full on May 29, 2026, or earlier if the next annual meeting of stockholders occurs before that date, contingent on Mr. Goeddel's continued service to the company.
• The expiration date for these stock options is May 28, 2035.
• This grant was made pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The document reports a routine insider equity grant, which is a neutral to slightly positive event as it aligns insider interests with company performance, but does not indicate any significant operational or financial news that would dramatically shift sentiment.

Positives

• The grant of stock options to a Director and 10% Owner aligns the interests of a significant insider with the long-term performance of Tenaya Therapeutics.
• The options provide an incentive for continued service and contribution from a key individual, fostering stability in leadership.

Negatives

• No direct negatives are apparent from this routine insider compensation filing.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The vesting schedule of the stock options, extending to May 29, 2026, indicates an expectation of continued service from David V. Goeddel to Tenaya Therapeutics, Inc., aligning his future contributions with the company's performance.

Management Comments

• "Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."
• "Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity compensation grant, which is a common practice across industries, particularly in biotechnology and growth-oriented companies, to incentivize and retain key personnel by aligning their financial interests with shareholder value. Such grants are a standard component of executive and director compensation packages.

Related Party Transactions

• The grant of 107,400 stock options to David V. Goeddel, who is both a Director and a 10% Owner, constitutes a related party transaction as it involves compensation from the issuer to an insider.

Stakeholder Impact

• **Shareholders**: The grant aligns the interests of a significant insider (Director and 10% Owner) with shareholder value creation, as the options gain value if the stock price increases. However, it also represents potential future dilution if and when these options are exercised.
• **Employees**: While this specific grant is to a director, the existence of an equity incentive plan (Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan) generally signals a commitment to equity-based compensation, which can be positive for overall employee morale and retention.

Next Steps

• Continued service of David V. Goeddel to Tenaya Therapeutics, Inc. to fulfill vesting conditions.
• Vesting of the 107,400 stock options on May 29, 2026, or earlier, based on the specified conditions.
• Potential exercise of options by David V. Goeddel before the expiration date of May 28, 2035, should the stock price be favorable.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Stock Option, Insider Transaction, Form 4, Equity Incentive Plan, Director Compensation, Beneficial Ownership, David V. Goeddel